We are live on ! Find out more
SPRO icon

Spero Therapeutics

47 hedge funds and large institutions have $21.3M invested in Spero Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

7% more funds holding

Funds holding: 4447 (+3)

0.29% more ownership

Funds ownership: 19.82%20.1% (+0.29%)

34% less capital invested

Capital invested by funds: $32.1M → $21.3M (-$10.9M)

45% less call options, than puts

Call options by funds: $195K | Put options by funds: $355K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
47
Holders Change
+3
Holders Change %
+6.82%
% of All Funds
0.62%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
14
Increased
12
Reduced
6
Closed
11
Calls
$195K
Puts
$355K
Net Calls
-$160K
Net Calls Change
+$775K
Name Holding Trade Value Shares
Change
Change in
Stake
Acadian Asset Management
51
Acadian Asset Management
Massachusetts
-$327K -112,889 Closed
Citadel Advisors
52
Citadel Advisors
Florida
-$228K -103,786 Closed
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
-$154K -69,814 Closed
QC
54
Quadrature Capital
United Kingdom
-$90.5K -31,205 Closed
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
-$17K -5,739 Closed
Raymond James Financial
56
Raymond James Financial
Florida
-$8.94K -3,082 Closed
CFB
57
Cullen/Frost Bankers
Texas
-$5.8K -2,000 Closed
TRCT
58
Tower Research Capital (TRC)
New York
-$1.75K -603 Closed

SPRO Hedge Fund Activity: Q3 2025 in Review

47 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2025, worth a combined $21.3M — down 34% from $32.1M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new SPRO positions and 11 closed out — a net gain of 3 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.36M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.48M sold.

  • 47 institutional investors held Spero Therapeutics (SPRO) as of Q3 2025, up from 44 in Q2 2025.
  • Funds reported $21.3M of Spero Therapeutics stock for Q3 2025, down 34% quarter-over-quarter.
  • 14 funds opened new Spero Therapeutics positions in Q3 2025 and 11 closed out, a net change of +3 holders.
  • The largest Spero Therapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $1.36M added.
  • The largest Spero Therapeutics seller in Q3 2025 was Schonfeld Strategic Advisors, an estimated $1.48M sold.

Based on aggregated 13F filings for Q3 2025.